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Purpose. This study is aimed at investigating the phenotype, differentiation potential, immunomodulatory properties, and responsiveness
of saphenous vein vessel wall-derived mesenchymal stromal cells (SV-MSCs) to various TLR ligands and proinflammatory cytokines, as
well as comparing their features to those of their bone marrow-derived counterparts (BM-MSCs). Methods. SV-MSCs were isolated by
enzymatic digestion of the saphenous vein vessel wall. Phenotype analysis was carried out by flow cytometry and microscopy, whereas
adipogenic, chondrogenic, and osteogenic differentiation potentials were tested in in vitro assays. For comparative analysis, the
expression of different stemness, proliferation, and differentiation-related genes was determined by Affymetrix gene array. To compare
the immunomodulatory properties of SV-MSCs and BM-MSCs, mixed lymphocyte reaction was applied. To investigate their
responses to various activating stimuli, MSCs were treated with TLR ligands (LPS, PolyI:C) or proinflammatory cytokines (TNFα, IL-
1β, IFNγ), and the expression of various early innate immune response-related genes was assessed by qPCR, while secretion of
selected cytokines and chemokines was measured by ELISA. Results. The isolated SV-MSCs were able to differentiate into bone, fat,
and cartilage cells/direction in vitro. SV-MSCs expressed the most important MSC markers (CD29, CD44, CD73, CD90, and CD105)
and shared almost identical phenotypic characteristics with BM-MSCs. Their gene expression pattern and activation pathways were
close to those of BM-MSCs. SV-MSCs showed better immunosuppressive activity inhibiting phytohemagglutinin-induced T
lymphocyte proliferation in vitro than BM-MSCs. Cellular responses to treatments mimicking inflammatory conditions were
comparable in the bone marrow- and saphenous vein-derived MSCs. Namely, similar to BM-MSCs, SV-MSCs secreted increased
amount of IL-6 and IL-8 after 12- or 24-hour treatment with LPS, PolyI:C, TNFα, or IL-1β, compared to untreated controls.
Interestingly, a different CXCL-10/IP-10 secretion pattern could be observed under inflammatory conditions in the two types of
MSCs. Conclusion. Based on our results, cells isolated from saphenous vein vessel wall fulfilled the ISCT’s (International Society for
Cellular Therapy) criteria for multipotent mesenchymal stromal cells, and no significant differences in the phenotype, gene expression
pattern, and responsiveness to inflammatory stimuli could be observed between BM-MSCs and SV-MSCs, while the latter cells have
more potent immunosuppressive activity in vitro. Further functional assays have to be performed to reveal whether SV-MSCs could
be useful for certain regenerative therapeutic applications or tissue engineering purposes.
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1. Introduction
Regeneration of blood vessels is essential for the homeostasis
of vasculature as well as in the restoration of various forms of
tissue injury. However, during inflammation or trauma, the
endothelial layer of the vessels has limited regeneration
potential. Furthermore, in many cases, the endothelium itself
is responsible for maintaining the inflammation, which could
lead to vessel malfunctions and tissue damage [1]. The
remodeling of the vasculature is an intricately controlled col-
laboration among stem/progenitor cells, immune cells, and
the residual cells of the vessel wall as well [2, 3]. This process
is balanced by proangiogenic and antiangiogenic factors
secreted by the cells mentioned above, and the vessels could
be regenerated by circulating stem cells, stromal cells, endo-
thelial progenitor cells, and vessel wall- or endothelium-
related progenitor cells in the subendothelial tissue [2–4]. Var-
ious cell types and rare cell populations have the properties to
differentiate to endothelial cells or to support the vasculogenic
processes [5]; however, resident vascular stem/progenitor and
stromal cells are thought to be a dominant subclass of the vas-
cular wall cell population involved in vascular homeostasis,
repair, and pathological processes [3, 6–13]. Mesenchymal
stromal cells (MSCs) were first isolated from the bone mar-
row [14, 15], but over the last decades, cells with multilineage
differentiation potential were also identified in many other
organs and tissues, especially within the perivascular area of
large vessels [16–18]. MSCs play a key role in the mainte-
nance of tissue integrity and homeostasis due to their differ-
entiation potential into another cell types and their
immunomodulatory capacity as well. However, responses of
MSCs to microbial stimuli, such as TLR ligands, or to proin-
flammatory cytokines are controversial topics, of which the
details are yet to be elucidated.
In this study, we made an extended comparison of saphe-
nous vein vessel wall-derived mesenchymal stem cells (SV-
MSCs) and bone marrow-derived mesenchymal stem cells
(BM-MSCs) regarding their phenotype, differentiation poten-
tial, immunomodulatory properties, and responsiveness to
various activating stimuli.
2. Materials and Methods
2.1. Bone Marrow, Saphenous Vein, and Umbilical Cord
Samples. Collections of bone marrow, umbilical cord, and
saphenous vein samples complied with the directive of the
Helsinki Declaration were approved by the institutional eth-
ical review board (Medical Research Council) of the Medical
and Health Science Center of the University of Debrecen
(Ethical protocol numbers: UD MHSC REC/IEC No. 2754-
2008, OSTRAT/1210-1/2008/OSTR). Tissue samples were
collected corresponding to the EU Member States’ Directive
2004/23/EC on tissue isolation [19].
For the isolation of BM-MSCs, approximately 10ml of
bone marrow aspirate was observed from the donors, which
were diluted with saline in 1 : 3 ratio. The mononuclear cells
were recovered by Ficoll Histopaque (Amersham Biosci-
ences, Uppsala, Sweden) density gradient centrifugation.
The number of live cells was determined by Trypan blue
exclusion assay. Bone marrow nucleated cells were plated in
25 cm2 flasks at a density of 2 × 105 living cells/cm2 and cul-
tured in DMEM-LG medium (DMEM with 1 g/L glucose,
Gibco/Invitrogen, London, UK), supplemented with 10%
FSC and 1% Antibiotic-Antimycotic Solution (PAA Labora-
tories GmbH, Pasching, Austria). After 3-4 days, the nonad-
herent cells were removed, and the cultures were reefed with
fresh medium. Thereafter, the cultures were fed every 3–4
days. When cells reached confluence, they were passaged
(P1) after 0.025% trypsin-EDTA (both Sigma-Aldrich, Buda-
pest, Hungary) application and replated into new 25 cm2
flasks. For positive BM-MSC control, MSCs from bone mar-
row were purchased from PromoCell (Heidelberg, Germany)
and cultured under the same conditions. At passage P5, phe-
notypic analyses by flow cytometry, in vitro differentiation
assays, and mycoplasma tests (Lonza, Basel, Switzerland)
were performed. Cells positive for mycoplasma were
excluded from the experiments.
Saphenous vein samples were collected from saphenec-
tomies. The samples were collected and transported in ice
cold PBS and processed within 4 hours. The vein was cleaned
of adipose or connective tissue and then cut into small pieces.
The segments were washed in PBS and then enzymatically
digested by 0.2mg/ml collagenase type XI (Sigma-Aldrich)
dissolved in DMEM-LG medium for 60 minutes at 37°C.
Cells were centrifuged at 1000 rpm for 20 minutes and
washed by DMEM-LG medium. After two washing steps,
cells were plated and cultured as described for BM-MSC.
The isolation and in vitro culture of human umbilical
vein endothelial cells (HUVECs) were described elsewhere
[20]. Briefly, HUVEC was removed from the umbilical cord
with 1% collagenase type XI (Sigma-Aldrich) digestion and
cultured in M199 medium (Sigma-Aldrich) supplemented
with 20% FCS (Gibco, London, UK), 1% Antibiotic-
Antimycotic Solution (PAA), and 1% L-glutamine (Gibco),
in CO2 incubator at 37
°C. After 4-5 days of culturing, when
cells reached confluence, they were trypsinized and inocu-
lated into new culture dishes. After 3 passages, the cell mono-
layers, which reached up to 70-80% confluence, were used for
the experiments.
2.2. Flow Cytometry and Immunochemistry. A multiparame-
ter analysis of the surface antigen expression of different
MSCs, an HUVECs was performed by three-color flow
cytometry using different fluorochrome-conjugated antibod-
ies: CD34, CD44, CD45, CD49f, CD73, CD106, CD144, and
CD147 (all from BD Biosciences, San Jose, CA, USA); CD49a
(Biolegend, San Diego, CA, USA), CD14, CD29, CD31,
CD36, CD47 CD49b, CD54, CD56, CD69, CD90, CD104,
CD105, CD117, CD146, CD166, CXCR4, HLA-DR,
PDGFRb, and VEGFR2 (all from R&D Systems, Minneapo-
lis, MN, USA); and CD133 (Miltenyi Biotech, Gladbach, Ger-
many). After harvesting the cells with 0.025% trypsin-EDTA,
cells were washed with normal medium and then twice with
FACS buffer. Cells were incubated with antibodies according
the manufacturers’ protocol on ice for 30min then washed
again with FACS buffer and fixed in 1% paraformaldehyde
(PFA)/PBS and analyzed within 1 day. Samples were mea-
sured by a FACSCalibur flow cytometer (BD Biosciences
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Immunocytometry Systems, Franklin Lakes, NJ, USA), and
data were analyzed using the FlowJo software (TreeStar, Ash-
land, OR, USA). Results were expressed as means of
positive cells ð%Þ ± SEM. For immunohistochemistry studies,
cell cultures were fixed in 4% PFA; then, samples were labeled
after washing the cells three times in PBS with primary anti-
bodies against iNOS (Calbiochem/Merck, Merck Millipore,
Darmstadt, Germany), von Willebrand factor (R&D Sys-
tems), and vimentin (Abcam, Cambridge, UK). Cell stain-
ings were visualized with NorthernLights fluorochrome-
conjugated secondary antibodies (R&D Systems). Actin fila-
ments were stained with phalloidin-TRITC (Sigma-Aldrich).
Nuclei were labeled with Hoechst 33342 (Invitrogen, Carls-
bad, CA, USA) samples mounted with mounting medium-
containing Mowiol (Merck) and glycerol in PBS and exam-
ined under an Olympus IX81 microscope equipped with a
Hamamatsu Orca2 camera.
2.3. In Vitro Differentiation Assays. Adipogenic, chondro-
genic, and osteogenic differentiations of MSC were performed
by using Gibco’s StemPro® Adipogenesis, Osteogenesis, and
Chondrogenesis Differentiation Kits (Gibco). All differentia-
tions were evaluated as per the manufacture’s guide.
2.4. RNA Isolation, cDNA Synthesis, QPCR, and Microarray
Data Analysis. Total RNA was isolated by TRIzol reagent
(Invitrogen). 1.5-2μg of total RNA was reverse transcribed
using SuperScript II RNase H reverse transcriptase (Invitro-
gen) and Oligo(dT)15 primers (Promega, Madison, WI,
USA). Gene-specific TaqMan assays (Applied Biosystems)
were used to perform QPCR in a final volume of 25μl in trip-
licates using AmpliTaq DNA polymerase and ABI Prism
7900HT real-time PCR instrument (Applied Biosystems).
Amplification of 36B4 and/or cyclophylin was used as nor-
malizing controls. Cycle threshold values (Ct) were deter-
mined using the SDS 2.1 software (Applied Biosystems).
Constant threshold values were set for each gene throughout
the study. The sequences of the primers and probes are avail-
able upon request.
To compare the gene expression profiles of different
MSCs, Affymetrix GeneChip Human Gene 1.0 ST Arrays
(Affymetrix, Santa Clara, CA, USA) were used as described
previously [21]. Based on the literature, stem/stromal cell-
related genes were selected, and statistical analysis was per-
formed (Oneway ANOVA with Tukey post hoc test and
Benjamini-Hochberg FDR) to calculate p value and fold
change. To identify the relationships between the selected
genes, the Ingenuity Pathway Analysis (IPA, Ingenuity Sys-
tems, Redwood City, CA, USA) was used. Excel datasheets
containing gene IDs with the assigned gene expression values
were uploaded into the program. The Ingenuity Pathways
Knowledge Base (IPKB) provided all known functions and
interactions which were published in the literature. For the
representation of the relationships between the genes, the
“Pathway Designer” tool of the IPA software was used.
2.5. Mixed Lymphocyte Reaction and Mitogen-Induced Cell
Proliferation. Peripheral blood mononuclear cells (PBMCs)
were isolated by a Ficoll gradient centrifugation (Amersham
Biosciences). Prior to the test, 104 and 105 MSCs were placed
in the cell culture plates, and nonadherent cells were removed
by a gentle wash step. PBMCs required for the MLR test
(1 × 106) were added 24 hours later. Mitogen-activated T
lymphocyte proliferation was induced by addition of conca-
navalin A (ConA) or phytohemagglutinin (PHA, both from
Sigma-Aldrich) at a final concentration of 10μg/ml and
1μg/ml, respectively, to the MSC-PBMC cocultures. On
day three, proliferation was detected by a BrDU colorimet-
ric assay directly in the cell culture plate according to the
manufacturer’s instructions (Roche, Budapest, Hungary).
In control experiments, MSCs and PBMCs were cultured
together or separately with and without mitogenic activa-
tion. To compare the immunosuppressive capacity of SV-
MSCs and BM-MSCs, the proliferation of mitogen-
activated PBMCs (OD values, BrdU incorporation) was
taken as value 1, and changes in BrdU incorporation caused
by MSCs were compared.
2.6. In Vitro Activation of MSC. To investigate the role of
TLR ligands and proinflammatory cytokines in MSCs, cells
were plated to 24-well plates at 5 × 104 cell density and then
incubated with 100ng/ml LPS (Sigma-Aldrich), 25μg/ml
PolyI:C (InvivoGen, San Diego, CA, USA), 100ng/ml TNFα,
10 ng/ml IFNγ, or 10 ng/ml IL-1β (all from Preprotech,
Rocky Hill, NJ, USA). After the incubation, the supernatant
was harvested and kept on -20°C until measurement. For
qPCR measurements, cells were plated to 25 cm2 flasks and
treated as mentioned above.
2.7. Measurement of Cytokine Secretion. Concentrations of
secreted IL-6 cytokine as well as IL-8 and CXCL-10/IP-10
chemokines were measured using OptEIA kits (BD Biosci-
ences) according to the manufacturer’s protocol. Cell culture
media were used as blank samples.
2.8. Statistical Analysis. The Statistica 7.0 software (StatSoft
Inc., Tulsa, OK, USA) was used for the statistical analyses.
Normality of distribution of data was assessed by
Kolmogorov-Smirnov and Lilliefors tests. Nonnormally dis-
tributed parameters were transformed logarithmically to cor-
rect their skewed distributions. The R software was used for
hierarchical clustering. Each experiment was performed at
least three times, and each sample was tested in triplicate.
Data are expressed asmean ± SD or SEM. Statistically signif-
icant difference was determined with two-way ANOVA anal-
ysis when there were more than two groups; for analysis
between two groups, paired Student t-test was used. Signifi-
cance level was set to 0.95; p values less than 0.05
(∗p < 0:05, ∗∗p < 0:01, ∗∗∗ p < 0:001) were considered
significant.
3. Results
3.1. Morphology, Differentiation Potential, and Phenotype of
SV-MSCs.MSCs isolated from saphenous vein showed simi-
lar morphology to bone marrow-derived MSCs (Figure 1(a)).
The cultured cells never formed a cobblestone pattern, and
their size was much larger than that of endothelial cells
(HUVECs), which were used as vein endothelial cell controls
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in our experiments (Figure 1(a)). After 2-3 passages on
adherent surface, the cells achieved uniform, fibroblast-like
morphology, and these cells could be propagated at least for
15 passages without further morphological changes. An
MSC type cell should fit the criteria defined by theMesenchy-
mal and Tissue Stem Cell Committee of the International
Society for Cellular Therapy (ISCT) regarding plastic adher-
ence, differentiation potential, and expression of cell surface
markers [22]. In the following experiments, it was examined
whether the SV-MSC cultures could be differentiated toward
canonical mesodermal (adipogenic, osteogenic, chondro-
genic) directions. Bone marrow-derived MSCs and SV-
MSCs were differentiated in vitro using adipogenic, osteo-















Figure 1: Comparison of morphology and multilineage differentiation potential of vessel wall- and bone marrow-derived MSCs. (a) After
passage 5, the isolated MSC populations derived from bone marrow (BM) or SV and human umbilical cord vein (HUVEC) exhibited
spindle-shaped morphology. (b) BM- and SV-derived MSCs exhibited the capability to differentiate into the three canonical differentiation
pathways, such as fat, bone, and cartilage. (c) Cytoskeletal actin labeled by phalloidin-TRITC, vimentin, and iNOS by rabbit monoclonal
antibody, visualized by anti-rabbit conjugated with NorthernLights493. Nuclei stained with Hoechst. Original magnification: ×200. Data is
representative of four experiments.
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weeks of adipogenic differentiation induction, a large num-
ber of the SV-MSCs and BM-MSCs showed oil red positive
staining, a characteristic for the adipocyte phenotype
(Figure 1(b)). In parallel cell cultures, dense calcium deposits
were detected after osteogenic differentiation (Figure 1(b)).
In sections made from chondrogenic mass culture after 3
weeks of differentiation, metachromasy was observed upon
toluidine-blue staining (Figure 1(b)). Both BM-MSC and
SV-MSC cultures were positive for vimentin and iNOS;
however, none of the cultures showed von Willebrand fac-
tor positivity, indicating the absence of endothelial cell
contamination (Figure 1(c)).
For a detailed characterization, we compared the expres-
sion of cell surface markers on BM-MSCs and SV-MSCs by
flow cytometry. As documented in Table 1, within the hema-
topoietic markers, no expression of CD34, CD45, CD69,
CD133, and the CXCL12 receptor CXCR4 could be detected
in the mesenchymal stromal cell cultures. A very small per-
centage of SV-MSCs was positive for CD117/c-kit
(0:02 ± 0:02%), while none of the BM-MSCs expressed this
marker. Neither BM-MSCs nor SV-MSCs expressed HLA-
DR antigen-presenting molecule. Due to the possibility of
endothelial contamination in SV-SMC cultures, we also
investigated the expression of endothelial specific markers.
CD31/PECAM, which makes up a large portion of endothe-
lial cells, was absent both in the bone marrow- and saphe-
nous vein-derived MSC cultures. The VEGFR2/KDR
expression was very low in HUVEC cultures and was totally
absent in MSC cultures. The expression of CD104/integrin β4
was more typical for the endothelial cells; however, it was also
expressed on MSCs. The percentage of CD144/VE-Cadherin
positive cells in SV-MSC cultures was in between those of
endothelial cells and BM-MSCs (Table 1). Any cell that is
described as mesenchymal stromal cell must fit the criteria
defined by ISCT. All the expected markers such as CD73
(ecto-5′-nucleotidase), CD90 (Thy-1), and CD105 (endoglin)
could be detected both on BM-MSCs and SV-MSCs. Although
CD73 and CD105 were also expressed by endothelial cells, the
ratio of CD90 expressing cells was low in the HUVEC cultures
(2:86 ± 1:55%), which distanced them from mesenchymal
stromal cell identity. No statistically significant differences
were found in the CD147 (neurothelin) and PDGFRβ expres-
sion among the three cell types. None of the ISCT defined
markers is exclusively MSC specific; therefore, we further
investigated the expression of integrins and other cell adhesion
molecules (CAMs), which determine the attachment and the
fate of the cells within the tissues. Only the percentage of the
melanoma cell adhesion molecule (CD146/MCAM) positive
cells was found to be significantly different in bone marrow-
(77:54 ± 5:14%) and saphenous vein-derived MSC cultures
(7:09 ± 6:56%). Besides CD146, the expression of CD54/inter-
cellular adhesion molecule 1 (ICAM-1), CD166/activated leu-
kocyte cell adhesion molecule (ALCAM), CD56/neural cell
adhesion molecule (NCAM), and CD44/homing-associated
cell adhesion molecule (H-CAM) could be detected in the cell
cultures; however, no significant differences were found in
their expression. The expression of CD29/integrin (Itg) β1
and CD49a/Itg α1 was similar in BM-MSC, SV-MSC, and
HUVEC cultures. In contrast, CD49b/Itg α2 was expressed
at a lower level on the surface of vessel wall-derived MSCs,
and the difference was found to be significant compared to
HUVECs (p = 0:0186), but it was not significant compared
to BM-MSCs. The CD49f/Itg α6 is mostly expressed by
smooth muscle stromal cells, fibroblasts, and epithelial cells.
MSCs isolated from either bone marrow or saphenous vein
vessel wall did not show CD49f positivity (Table 1).
Using a cluster analysis on the expression of the above
surface markers in the three cell types, we found a clear divi-
sion of the endothelial cells from the mesenchymal stromal
cells (Figure 2). Results on SV-MSCs from different donors
integrated well into the BM-MSC cluster despite interdonor
variability. These observations indicate that our isolation
technique with the applied phenotype analysis is suitable to
detect mesenchymal stromal cells isolated from vessel wall
(Figure 2).
3.2. Gene Expression Analysis. Next, the gene expression pro-
files of BM-MSCs and SV-MSCs were compared using
microarray analyses. Genes related to differentiation and lin-
eage (489 genes), stemness (422 genes), HOX (homeobox),
SOCS (suppressor of cytokine signaling) and Notch signaling
(380 genes), and cell cycle, oncogenes (242 genes) were col-
lected into functional groups and analyzed. The hierarchical
clustering clearly divided the cells with bone marrow and
vessel wall origin in the case of differentiation and lineage,
stemness and HOX, SOCS, and Notch signaling custom
groups (Figure 3). The gene expression profile of SV-MSCs
in the cell cycle and oncogenes custom group was not signif-
icantly different from that of their BM-MSC counterpart
(Figure 3); however, several genes related to this biological
function group were differentially expressed in BM-MSCs
and SV-MSCs (Table 2). In SV-MSCs, expression level of
S100A4 (S100 calcium binding protein A4) was significantly
higher (2.8-fold change), whereas that of SMAD3 (SMAD
family member 3) and CDK6 (cyclin-dependent kinase 6)
was significantly lower (-2.6- and -2.2-fold change, respec-
tively) than in BM-MSCs (Table 2). Significantly upregulated
(≥2-fold) genes related to differentiation in SV-MSCs were
found to be PODXL (podocalyxin-like), CTSK (cathepsin
K), and CSF1 (colony stimulating factor 1/macrophage),
while VCAM1 (vascular cell adhesion molecule 1), ACAN
(aggrecan), EGR2 (early growth response 2), TGFB2 (trans-
forming growth factor beta 2), IGF2 (insulin-like growth fac-
tor 2), BMP2 (bone morphogenetic protein 2), BDNF (brain-
derived neurotrophic factor), JAG1 (jagged 1), INHBA
(inhibin, beta A), ITGA3 (integrin, alpha 3), SMAD3, HES1
(hairy and enhancer of split 1), EFNB2 (ephrin-B2), PTN
(pleiotrophin), and PDGFA (platelet-derived growth factor
alpha) genes were significantly downregulated (≤ -2-fold).
An SV-MSC-specific pattern of stemness could be character-
ized with high expression of FGF9 (fibroblast growth factor 9
or glia-activating factor), ZFPM2 (zinc finger protein, multi-
type 2), MME (membrane metallo-endopeptidase), and
FZD4 (frizzled homolog 4) genes, together with low expres-
sion of LIF (leukemia inhibitory factor or cholinergic differ-
entiation factor), MGC20647 (hypothetical protein
MGC20647), CXCL12 (chemokine C-X-C motif ligand 12
or stromal cell-derived factor 1), MCAM (melanoma cell
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adhesion molecule), ACAN, LTBP1 (latent transforming
growth factor beta binding protein 1), BMP2, SMAD3,
ALCAM, ITGAV (integrin, alpha V, or vitronectin receptor),
GDF6 (growth differentiation factor 6), and FGF7 (fibroblast
growth factor 7) genes (Table 2). In the HOX, SOCS, and
Notch signaling, superfamily FGF9, IL-33 (interleukin-33),
and HOXA11 (homeobox A11) genes were determined as sig-
nificantly upregulated (≥2-fold) ones in SV-MSCs (Table 2).
Focusing on the expression of MSC-related genes, our micro-
array data were validated by a qPCR-based gene array as well
(Supplementary Figure 1). During characterization of MSCs,
the study of senescence is particularly important. Our gene
expression analysis revealed that only 18 out of 160 genes
known to be important in the development of senescence are
expressed differently in BM- and SV-MSCs (Supplementary
Figure 2 and Supplementary Table 1). CHEK2, GAA, TP53,
CDKN1A, SQSTM1, CTSB, GLB1, ATP6V1G2, and ETS2
genes were upregulated, while MCL1, CDK6, BAT1, TGFB1,
FN1, PLAU, GALNT5, IGF1R, and IGFBP7 genes were
downregulated in SV-MSCs compared to BM-MSCs. Most
of the upregulated genes are responsible for maintaining
replicative capacity and inhibiting cellular senescence. Taken
together, our data suggest that BM-MSCs and SV-MSCs
display very similar pattern of the gene expression.
3.3. Immunomodulatory Properties of BM-MSCs and SV-
MSCs. The immunosuppressive properties of MSCs have
been extensively studied over the past years, for their
Table 1: Detailed phenotypic analysis of BM-MSCs and SV-MSCs.
BM-MSC SV-MSC HUVEC
Percentage of positive cells (%)
Hematopoietic markers
CD14 0:22 ± 0:11 1:37 + 1:15 0 + 0
CD34 0 ± 0 0 ± 0 4:62 + 2:05
CD36 32:51 ± 8:18 18:12 ± 5:28 36:6 + 17:60
CD45 0 ± 0 0 ± 0 0 + 0
CD47 97:00 ± 0:86 96:65 ± 1:55 85:06 + 12:49
CD69 0 ± 0 0 ± 0 27:24 + 10:93
CD133 0 ± 0 0 ± 0 0 + 012:03
CD117 0 ± 0 0:02 ± 0:02 81:57 + 11:26∗∗∗
CXCR4 0 ± 0 0 ± 0 37:37 + 8:18∗∗
HLA-DR 0 ± 0 0 ± 0 0:19 + 0:12
Endothelial markers
CD31 0 ± 0 0 ± 0 96:78 + 0:82∗∗∗
CD144 45:33 ± 12:61 61:55 ± 18:18 93:91 + 2:45
VEGFR2/KDR 0 ± 0 0 ± 0 0:75 + 0:41
CD104/integrin β4 28:25 ± 12:20 34:42 ± 17:82 76:42 + 11:50
MSC/fibroblast markers
CD73 91:99 ± 1:92 97:90 ± 0:80 97:85 + 0:94
CD90/Thy-1 89:05 ± 1:49 89:68 ± 3:63 2:86 + 1:55∗∗∗
CD105/endoglin 82:64 ± 2:56 89:62 ± 2:54 97:94 + 0:52∗∗∗
CD147/neurothelin 77:33 ± 8:87 81:11 ± 13:59 98:31 + 0:91
PDGF Rβ 78:01 ± 8:28 90:77 ± 3:74 54:67 + 11:90
Cell adhesion molecules
CD29/integrin β1 92:96 ± 1:71 97:02 ± 1:87 98:77 + 0:64
CD44/H-CAM 87:28 ± 2:87 88:66 ± 2:38 79:28 + 5:06
CD49a 79:60 ± 7:77 94:25 ± 1:55 89:44 + 1:64
CD49b 68:52 ± 7:95 48:44 ± 12:25 85:32 + 5:42∗
CD49f 0 ± 0 0 ± 0 2:21 + 1:27
CD54/ICAM 14:95 + 8:36 19:89 + 8:59 34:29 + 7:24
CD56/NCAM 20:53 ± 8:41 19:18 ± 9:10 50:33 + 7:94
CD146/MCAM 77:54 ± 5:14∗∗∗ 7:09 ± 6:56 96:68 + 1:02∗∗∗
CD166/ALCAM 89:57 ± 6:27 96:22 ± 2:13 98:54 + 0:45
Expression of surface markers related to different cell types was measured by flow cytometry. The percentage of positive cells in SV-MSC culture was compared
to that of BM-MSCs as well as HUVECs, as vein endothelial control. (Data are presented asmeans ± SEM; N = 5 for SV-MSC, N = 12 for BM-MSC, N = 7 for
HUVEC. p < 0:05∗, p < 0:01∗∗, p < 0:001∗∗∗ vs. SV-MSCs determined by Student t-test).
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promising clinical application potential. In the present study,
mitogenic mixed lymphocyte reaction (MLR) was used to
compare the immunosuppressive properties of BM-MSCs
and SV-MSCs. Human PBMCs from healthy donors were
applied as responder cells and ConA or PHA as mitogenic
activators. As expected, PBMCs proliferated in response to
ConA or PHA treatment (data not shown). The addition of
either BM-MSCs or SC-MSCs to PBMCs stimulated with
ConA resulted in a moderate, statistically insignificant reduc-
tion of BrDU incorporation (Figure 4). In contrast, statisti-
cally significant suppressions of lymphocyte proliferation by
both BM-MSCs and SV-MSCs could be detected in PBMCs
cultures activated with PHA (Figure 4). At both cell ratios
(MSC/PBMC 1 : 100 and 1 : 10), the suppression of PBMC
proliferation by SV-MSCs was more prominent; however, a
significant difference between SV-MSCs and BM-MSCs in
their suppressive effects was observed only at a ratio of
1 : 100 (Figure 4).
3.4. Activation of BM-MSCs and SV-MSCs. Although the
immunosuppressive function of MSCs is well described,
much fewer details are available about their response to pro-
inflammatory cytokine exposure or TLR ligand activation,
especially in case of vessel wall-derived MSCs. Therefore, in
the next series of our experiments, BM-MSCs and SV-
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Figure 2: Hierarchical clustering of surface markers expressed by BM-MSCs and SV-MSCs. Robust hierarchical clustering of cell surface
molecules’ expression divided the BM-MSCs and SV-MSCs from the endothelial cells isolated from the umbilical cord tissue (HUVEC).
SV-MSCs were more closely related to BM-MSC than to endothelial cells (a). (Color key represents percentage of positive cells in the

























































































































































Figure 3: Heat maps of the differentially expressed genes in BM-MSCs and SV-MSCs. Genes related to stemness, HOX, Notch and SOX
signaling, differentiation and lineage, cell cycle, and oncogenes were selected. The functional cluster analysis of the different expression
levels of selected genes shows the difference between the cell types suggesting different tissue origin. (Color key represents relative gene
expression levels.)
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Table 2: Top up- and downregulated custom selected genes in SV-MSCs.
Symbol Entrez gene name
Fold
change
p value Molecule type Group
Fold change upregulated
S100A4 S100 calcium binding protein A4 2.805862 0.0426795 Calcium binding protein
Cell cycle and
oncogenes
CDH1 Cadherin 1, type 1, E-cadherin (epithelial) 1.61272 0.0221517 Cell adhesion molecule
BRCA2 Breast cancer 2, early onset 1.36718 0.0158221 DNA repair
SMG6
Smg-6 homolog, nonsense mediated mRNA decay
factor (C, elegans)
1.1617644 0.0169296 Enzyme






IL-33 Interleukin-33 2.8804057 0.0380778 Cytokine
HOXA11 Homeobox A11 2.00343 0.0164048 Transcription factor
BMP4 Bone morphogenetic protein 4 1.8365396 0.0429056
Growth and
differentiation factor
PODXL Podocalyxin-like 4.6124125 0.0230397 Cell differentiation
Differentiation
and lineage
CTSK Cathepsin K 2.5564253 0.0201834
Lysosomal cysteine
protease
CSF1 Colony stimulating factor 1 (macrophage) 2.176855 0.0155533 Cytokine
TGFB3 Transforming growth factor, beta 3 1.8547666 0.0230397
Growth and
differentiation factor
NRP1 Neuropilin 1 1.7981821 0.0058021
Membrane-bound
coreceptor
GDF10 Growth differentiation factor 10 1.6743402 0.0155533
Growth and
differentiation factor




ZFPM2 Zinc finger protein, multitype 2 5.1527076 0.0195738 Transcription factor
MME Membrane metallo-endopeptidase 3.1862447 0.0245681 Enzyme
FZD4 Frizzled homolog 4 (drosophila) 2.4862442 0.0143408 Receptor
ACVRL1 Activin A receptor type II-like 1 1.8575617 0.0143408 Enzyme
Fold change downregulated





CDK6 Cyclin-dependent kinase 6 -2.243104 0.0237225 Enzyme
KRAS|LYRM5
v-Ki-ras2 Kirsten rat sarcoma viral oncogene
homolog|LYR motif containing 5
-1.901833 0.0461384 Proto-oncogene
TGFB1 Transforming growth factor, beta 1 -1.731404 0.0158221
Growth and
differentiation factor
RARA Retinoic acid receptor, alpha -1.566421 0.0337291 Nuclear receptor




Sad1 and UNC84 domain containing 1|chromosome
7 open reading frame 20
-1.263087 0.0108465 Nuclear envelope protein








HOXA2 Homeobox A2 -1.6179696 0.0280393 Transcription factor
SNAI1 Snail homolog 1 (drosophila) -1.6272678 0.0442530 Transcription factor
PYGO1 Pygopus homolog 1 (drosophila) -1.6621072 0.0924799
NOTCH2 Notch homolog 2 (drosophila) -1.6733813 0.0177410 Transmembrane protein
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for 12 and 24 hours, and the expression of various early
innate immune response-related genes was investigated. As
shown in Figure 5, the mRNA expression level of a dsRNA
sensor RIG-I (retinoic acid-inducible gene I) was increased
after 12 and 24 hours upon PolyI:C and IFNγ treatment both
in BM-MSCs and SV-MSCs. Activation with PolyI:C also
induced a marked rise in the expression of MDA5, another
dsRNA sensor of the RIG-I-like receptor family [23]. Induc-
tion of both RIG-I and MDA5 gene expression was more
robust in BM-MSCs. The expression of IL-6 gene was
increased upon LPS, PolyI:C, and TNFα treatments at both
time points in both MSC types. The IFNβ expression was
markedly upregulated in the case of PolyI:C activation fol-
lowing 12- and 24-hour treatments in both type of MSCs.
A robust increase in the gene expression level of CXCL-
10/IP-10 (interferon gamma-induced protein 10) was
observed when MSCs were treated with PolyI:C at both time
points (Figure 5). Inducible nitrogen-oxide synthase (iNOS)
Table 2: Continued.
Symbol Entrez gene name
Fold
change
p value Molecule type Group
MAML2 Mastermind-like 2 (drosophila) -1.6876673 0.0481715
Transcriptional
coactivator
VCAM1 Vascular cell adhesion molecule 1 -17.354261 0.0058021
Differentiation
and lineage
ACAN Aggrecan -5.5746202 0.0192411
EGR2 Early growth response 2 -4.387574 0.0191151
TGFB2 Transforming growth factor, beta 2 -3.9135396 0.0058021
IGF2|INS-
IGF2
Insulin-like growth factor 2 (somatomedin A)|INS-
IGF2 readthrough transcript
-3.4904327 0.0192411
BMP2 Bone morphogenetic protein 2 -3.314717 0.0230696
BDNF Brain-derived neurotrophic factor -3.2864723 0.0155533
JAG1 Jagged 1 (Alagille syndrome) -3.0462105 0.0058021
INHBA Inhibin, beta A -2.8667028 0.0422998
ITGA3
Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of
VLA-3 receptor)
-2.775381 0.0155533
SMAD3 SMAD family member 3 -2.5795743 0.0078861
HES1 Hairy and enhancer of split 1 (drosophila) -2.220433 0.0192411
EFNB2 Ephrin-B2 -2.1113176 0.0358564
PTN Pleiotrophin -2.1063795 0.0155533
PDGFA
LOC100132080










Chemokine (C-X-C motif) ligand 12|chemokine (C-
X-C motif) ligand 12 (stromal cell-derived factor 1)
-8.499458 0.0414186
MCAM Melanoma cell adhesion molecule -5.909656 0.0080718
ACAN Aggrecan -5.5746202 0.0193145
LTBP1
Latent transforming growth factor beta binding
protein 1
-4.3929467 0.0398936
BMP2 Bone morphogenetic protein 2 -3.314717 0.0236414
SMAD3 SMAD family member 3 -2.5795743 0.0087946
ALCAM Activated leukocyte cell adhesion molecule -2.1179285 0.0080718
ITGAV
Integrin, alpha V (vitronectin receptor, alpha
polypeptide, antigen CD51)
-2.0977302 0.0143408
GDF6 Growth differentiation factor 6 -2.054666 0.0427049
FGF7
Fibroblast growth factor 7 (keratinocyte growth
factor)
-2.0363815 0.049803
FGFR2 Fibroblast growth factor receptor 2 -1.8906314 0.0324610
Top up- and downregulated genes in SV-MSCs related to stemness, HOX, Notch and SOX signaling, differentiation and lineage, cell cycle, and oncogenes were
selected by the significance.
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is a key element of MSC-mediated immunosuppression [24].
The expression of iNOS was notably induced in SV-MSCs
after a 24-hour PolyI:C treatment, whereas its expression
level in BM-MSCs remained almost unchanged under the
same conditions. Overall, there were no significant differ-
ences between SV-MSCs and BM-MSCs in the expression
pattern of genes associated with TRL ligand- and proin-
flammatory cytokine-triggered activation (Supplementary
Figure 3).
To validate our findings at protein level, secreted cyto-
kine and chemokine concentrations were also determined
in MSC cultures upon activation of the cells with TLR ligands
or proinflammatory cytokines (Figure 6). IL-6 was constantly
secreted by both types of MSCs under normal conditions.
Secretion patterns of IL-6 cytokine and IL-8 chemokine were
similar in both MSC cultures. Exposure to LPS, PolyI:C,
TNFα, or IL-1β for 12 and 24 hours triggered a significant
increase in the concentrations of both above mentioned
secreted mediators, whereas treatments with IFNγ did not
modify their production by BM-MSCs and SV-MSCs. More
intense IL-6 and IL-8 production was observed in BM-MSC
than SV-MSC culture (Figure 6). Both type of MSCs secreted
CXCL-10/IP-10 chemokine upon TLR- and cytokine recep-
tor ligation. In contrast to IL-6 and IL-8 levels, SV-MSCs
produced more CXCL-10/IP-10 in response to activation
than BM-MSCs. Based on our measurements, in BM-MSCs
cultures, PolyI:C and IL-1β stimuli were the most potent
inducers of CXCL-10/IP-10 production, while SV-MSCs
released this chemokine in increased concentrations as a
result of any applied activations; however, the changes were
statistically significant only when the cells were exposed to
the TLR ligands, LPS, or PolyI:C (Figure 6).
4. Discussion
Mesenchymal stromal cells reside in various tissues of meso-
dermal origin. They are multipotent cells, which are able to
differentiate into various types of specialized cells including
osteoblasts, chondrocytes, and adipocytes [25]. This ability
endows MSCs with a broad regenerative potential in adult
tissues [26]. However, MSCs do not only contribute to tissue
repair processes but also have strong immunomodulatory
properties and may inhibit inflammation by modulation of
local environment [27].
In this study, we separated MSCs from saphenous vein
vessel wall and compared their morphology, phenotype,
and functions to those of bone marrow-derived MSCs to
reveal the differences and similarities, which could be associ-
ated with their regulatory role in angiogenesis or their immu-
nomodulatory properties under physiologic and pathologic
conditions. Pericytes and MSCs share morphology, expres-
sion of several cell surface molecules, and even differentiation
potential in vitro; however, MSCs can be characterized by a
combination of perivascular (CD146, PDGFRβ) and MSC
markers (CD29, CD44, CD73, CD90, CD105) as well as by
the lack the expression of hemato-endothelial cell markers
(CD31, CD34, CD45, CD144) [28]. According to our find-
ings, the cells isolated from saphenous vein (SV-MSC)
showed similar morphology to bone marrow-derived MSCs


















































Figure 4: Immunomodulatory effect of SV- and BM-MSCs in vitro. Fold change in PBMCs’ proliferation showed that bone marrow- and
vessel wall-derived MSCs were capable to inhibit the proliferation of lymphocytes activated by either PHA or ConA in vitro; however,








































































































































































































Figure 5: Relative expression levels of selected genes in MSCs derived from bone marrow and saphenous vein in resting and stimulated cells.
Mesenchymal stromal cells were treated with 100 ng/ml LPS, 25 μg/ml PolyI:C, 100 ng/ml TNFα, 10 ng/ml IL-1β, or 10 ng/ml IFNγ for 12 and
24 hours as described in Methods. Relative levels of mRNA were measured in triplicates by qPCR, and fold changes in the gene expression
were calculated from the ratio of expression levels in treated and untreated cells as mean ± SEM (N = 3 in both cell types).
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differentiate toward multiple mesodermal lineages including
fat, bone, and cartilage cells. SV-MSC cultures could be dif-
ferentiated toward canonical mesodermal; adipogenic, osteo-
blastic, and chondrogenic directions culturing the cells in the
appropriate induction media. Similar to BM-MSCs, the SV-
MSCs are also fit to the criteria defined by ISCT, which
means that all expected markers could be detected. The
populations of BM- and SV-MSCs were well identified;
they differed from the myoblasts, smooth muscle cell pre-
cursors, or from the control HUVEC cells. The only sig-
nificant difference identified was the higher expression of
CD146 on the surface of BM-MSCs than on that of SV-
MSCs. Previous findings in in vitro and animal models
suggest that higher CD146 level on MSCs is associated
with more plasticity, better ability for transendothelial
migration but lower regenerative potential of the cells
[29, 30]. Further studies examining the human relevance
of these observations need to be performed.
Our results provide an evidence that the isolation tech-
nique invented by our group is suitable to collect a pure vessel
wall-derived mesenchymal stromal cell population. To inves-
tigate differences and similarities between the gene expres-
sion profile of BM-MSCs and SV-MSCs, we examined the
genes related to differentiation and lineage, stemness, HOX,
SOCS, Notch signaling, cell cycle, and oncogenes. These data
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Figure 6: Cytokine secretion by activated MSCs derived from bone marrow and saphenous vein. IL-6, IL-8, and IP-10 cytokine production of
TRL ligands (LPS, PolyI:C), as well as proinflammatory cytokine- (TNFα, IFNγ, IL-1β) stimulated MSCs. In vitro cultured cells were treated
in 12 h and 24 h intervals. (Data shown are mean ± SD; p < 0:05∗, p < 0:01∗∗, p < 0:001∗∗∗; N = 6 for the BM-MSCs and N = 3 for the SV-
MSCs, respectively.)
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the functional properties of the BM-MSCs and SV-MSCs.
According to the hierarchical clustering in case of the genes
related to the cell cycle and oncogenes custom group, we
did not detect any significant difference between the BM-
and SV-MSCs. In contrast, the expression profile clearly
divided the cells isolated from bone marrow and saphenous
vein into two groups in case of the differentiation and lineage,
stemness and HOX, SOCS, and Notch signaling groups as
well as senescence. Above described differences could be the
consequences of the variant origin and localisation of MSCs
[31], functions of BM-MSCs in the bone marrow to support
the differentiation and survival of hematopoietic stem cells
(HSC) while the SV-MSCs are responsible for the regenera-
tion and wound healing, angiogenesis, and neovasculariza-
tion [32]. The immunosuppressive activity of BM-MSCs is
already published in details underlying their importance in
the treatment or their possible application in case of a wide
array of nonphysiologic conditions like autoimmune and
inflammatory diseases or cancer. Based on our present data,
we can state that SV-MSCs also have a potential to suppress
the mitogenic activation of PBMCs. Moreover, in our exper-
iments, SV-MSCs displayed better immunosuppressive activ-
ity inhibiting PHA-induced T lymphocyte proliferation
in vitro than BM-MSCs.
When MSCs are exposed to degraded ECM products,
they exhibited an increased migratory capability [33]. These
changes prove the activation of MSCs in the presence of var-
ious stimuli such as injury, infection, or sterile inflammation
resulted in the enhanced secretion of various cytokines, like
basic-fibroblast growth factor (b-FGF), chemotactic and
mitogenic molecules, or vascular endothelial growth factor
(VEGF) modulating the angiogenesis [34]. Like many other
cells, the MSCs also express extra- and intracellular pattern
recognition receptors (PRRs). Immunomodulatory functions
of MSCs can be influenced by either ligation of PRRs or via
exposure to cytokines and other immunomodulatory factors
[35]. Response of MSCs to different stimulatory factors
determinates the differentiation and functions of neighbour-
ing immune and not immune cells thus the immune
responses themselves [36, 37]. Both BM- and SV-MSCs
could be stimulated by PolyI:C leading to the increased
expression of RIG-I, MDA5, IL-6, IFNβ, CXCL-10/IP-10,
and iNOS. However, we detected differences in the intensity
of cellular responses following the PolyI:C treatments. BM-
MSCs are able to react to PolyI:C to a greater extent by
expressing higher levels of RIG-I, MDA-5, IFNβ, and
CXCL-10/IP-10 than SV-MSCs. In agreement with previous
findings [38], both BM-MSCs and SV-MSCs could be acti-
vated with LPS despite the fact that MSCs express CD14,
which plays a vital role in TLR4 signaling pathway, at a very
low level. LPS treatment may induce slight expression of
cytokines and chemokines in MSCs without activation of
AKT, NF-κB, and P38 [38]. TLR and cytokine receptor liga-
tion resulting in upregulated secretion of IL-6, IL-8, and
CXCL-10/IP-10, although a treatment with IFNγ had no
effect on their cytokine and chemokine production. Priming
of MSCs by PRR ligands to alter their immunomodulatory
activity is known to be essential to use these cells in the treat-
ment of various diseases [39]; however, it seems that MSCs
isolated from bone marrow or saphenous vein respond to
priming stimuli in slightly different ways.
Under physiologic and pathologic conditions, MSCs
express a wide array of surface markers and produce various
factors by which they can communicate with different cell
types including immune cells. The immunomodulatory capac-
ity of MSCs may result in the inhibited proliferation of lym-
phocytes and suppressed function of activated inflammatory
cells. Furthermore, they are able to drive and determine the
differentiation of myeloid-derived cells and the polarization
of the T cell response [40]. Based on our results, SV-MSCs ful-
fill the ISCT criteria for multipotent mesenchymal stromal
cells and share almost identical phenotypic and functional
characteristics with BM-MSCs. Furthermore, SV-MSCs are
easy to obtain and could be alternative sources of MSCs with
tissue origin. Therefore, SV-MSCs can be considered as good
candidate for further thorough investigations (e.g., assays test-
ing proliferative capacity, sensitivity to apoptosis, and karyo-
type changes during replication) to reveal whether these cells
could be useful for certain regenerative therapeutic and tissue
engineering applications (e.g., 3D bioprinting).
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